KCNH2 polymorphism and methadone dosage interact to enhance QT duration

Drug and Alcohol Dependence

Volumn 141, Issue , 2014, Pages 34-38

  Hajj, Aline ^a,b,c   Ksouda, Kamilia ^a,d   Peoc'h, Katell ^a,b   Curis, Emmanuel ^a,e   Messali, Anne ^f   Deveaux, Laurence Labat ^g   Bloch, Vanessa ^a   Prince, Nathalie ^a   Mouly, Stéphane ^a   Scherrmann, Jean Michel ^a   Lépine, Jean Pierre ^a,d   Laplanche, Jean Louis ^a,b   Drici, Milou Daniel ^h   Vorspan, Florence ^a,d  

^a Inserm UMR S 1144   (France)

^b Service de Biochimie   (France)

^c SAINT JOSEPH UNIVERSITY   (Lebanon)

^d Service de Psychiatrie   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f AP HP HÔpital Lariboisière Service de Cardiologie   (France)

^g HÔTEL DIEU   (France)

^h Centre de Pharmacologie   (France)

Author keywords

Channelopathies; Methadone; QT interval; Repolarization reserve

Indexed keywords

BENZODIAZEPINE; CHLORPROMAZINE; LYSINE; METHADONE; THREONINE; ERG1 POTASSIUM CHANNEL; NARCOTIC AGENT; POTASSIUM CHANNEL HERG;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CODON; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEART REPOLARIZATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KCNE1 GENE; KCNE2 GENE; KCNH2 GENE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OPIATE ADDICTION; PHARMACOGENETICS; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TORSADE DES POINTES; TREATMENT DURATION; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HEART; HEART MUSCLE CONDUCTION SYSTEM; HEROIN DEPENDENCE; LONG QT SYNDROME; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; YOUNG ADULT;

ADULT; AGED; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GENE-ENVIRONMENT INTERACTION; GENOTYPE; HEART; HEART CONDUCTION SYSTEM; HEROIN DEPENDENCE; HUMANS; LONG QT SYNDROME; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84903164264     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.04.027     Document Type: Article

References (34)

1. Abbott G.W., Sesti F., Splawski I., Buck M.E., Lehmann M.H., Timothy K., Keating M.T., Goldstein S.A. MiRP1 forms IKr potassium channels with HERG and is associated with cardia arrhytmia. Cell 1999, 97:157-187.
2. Al-Khatib S.M., LaPointe N.M., Kramer J.M., Califf R.M. What clinicians should know about the QT interval. J. Am. Med. Assoc. 2003, 289:2120-2127.
3. Anchersen K., Hansteen V., Gossop M., Clausen T., Waal H. Opioid maintenance patients with QTc prolongation: congenital long QT syndrome mutation may be a contributing risk factor. Drug Alcohol Depend. 2010, 112:216-219.
4. Ansermot N., Albayrak O., Schlapfer J., Crettol S., Croquette-Krokar M., Bourquin M., Eap C.B. Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval. Arch. Intern. Med. 2010, 170:529-536.
5. Bezzina C.R., Verkerk A.O., Busjahn A., Jeron A., Erdmann J., Koopmann T.T., Wilde A.A. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc. Res. 2003, 59:27-36.
6. Brugada R., Hong K., Dumaine R., Cordeiro J., Gaita F., Borggrefe M., Antzelevitch C. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004, 109:30-35.
7. Butler B., Rubin G., Lawrance A., Batey R., Bell J. Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction. Drug Alcohol Rev. 2011, 30:173-180.
8. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R.J., Taylor R.S. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol. Assess. 2007, 11:1-171. (iii-iv).
9. Dalageorgou C., Ge D., Jamshidi Y., Nolte I.M., Riese H., Savelieva I., Snieder H. Heritability of QT interval: how much is explained by genes for resting heart rate?. J. Cardiovasc. Electrophysiol. 2008, 19:386-391.
10. De Bels D., Staroukine M., Devriendt J. Torsades de pointes due to methadone. Ann. Intern. Med. 2003, 139:E156.
11. Doran C.M., Shanahan M., Mattick R.P., Ali R., White J., Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003, 71:295-302.
12. Ehret G.B., Voide C., Gex-Fabry M., Chabert J., Shah D., Broers B., Desmeules J.A. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch. Intern. Med. 2006, 166:1280-1287.
13. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Annual Report 2012, http://www.emcdda.europa.eu/online/annual-report/2012 (accessed 10.09.13).
14. Gil M., Sala M., Anguera I., Chapinal O., Cervantes M., Guma J.R., Segura F. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am. J. Cardiol. 2003, 92:995-997.
15. Goldenberg I., Moss A.J. Long QT syndrome. J. Am. Coll. Cardiol. 2008, 51:2291-2300.
16. Gouas L., Nicaud V., Berthet M., Forhan A., Tiret L., Balkau B., Guicheney P. Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population. Eur. J. Hum. Genet. 2005, 13:1213-1222.
17. Gouas L., Nicaud V., Chaouch S., Berthet M., Forhan A., Tichet J., Guicheney P. Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects. Eur. J. Hum. Genet. 2007, 15:974-979.
18. Gustina A.S., Trudeau M.C. hERG potassium channel gating is mediated by N- and C-terminal region interactions. J. Gen. Physiol. 2011, 137:315-325.
19. Judson R.S., Salisbury B.A., Reed C.R., Ackerman M.J. Pharmacogenetic issues in thorough QT trials. Mol. Diagn. Ther. 2006, 10:153-162.
20. Katchman A.N., McGroary K.A., Kilborn M.J., Kornick C.A., Manfredi P.L., Woosley R.L., Ebert S.N. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J. Pharmacol. Exp. Ther. 2002, 303:688-694.
21. Katz D.F., Sun J., Khatri V., Kao D., Bucher-Batelson B., Traut C., Lundin-Martinez J., Goodman M., Mehler P.S., Krantz M.J. QTc interval screening in an opioid treatment program. Am. J. Cardiol. 2013, 112:1013-1018.
22. Kleber H.D. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. J. Am. Med. Assoc. 2008, 300:2303-2305.
23. Krantz M.J., Lewkowiez L., Hays H., Woodroffe M.A., Robertson A.D., Mehler P.S. Torsade de Pointes associated with very-high-dose methadone. Ann. Intern. Med. 2002, 137:501-504.
24. Krantz M.J., Rowan S.B., Mehler P.S. Cocaine-related torsade de pointes in a methadone maintenance patient. J. Addict. Dis. 2005, 24:53-60.
25. Lipski J., Stimmel B., Donoso E. The effect of heroin and multiple drug abuse on the electrocardiogram. Am. Heart J. 1973, 86:663-668.
26. Maremmani I., Pacini M., Cesaroni C., Lovrecic M., Perugi G., Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur. Addict. Res. 2005, 11:44-49.
27. Marjamaa A., Newton-Cheh C., Porthan K., Reunanen A., Lahermo P., Vaananen H., Salomaa V. Common candidate gene variants are associated with QT interval duration in the general population. J. Intern. Med. 2009, 265:448-458.
28. Martell B.A., Arnsten J.H., Krantz M.J., Gourevitch M.N. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am. J. Cardiol. 2005, 95:915-918.
29. Mayet S., Gossop M., Lintzeris N., Markides V., Strang J. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?. Drug Alcohol Rev. 2011, 30:388-396.
30. Newton-Cheh C., Guo C.Y., Larson M.G., Musone S.L., Surti A., Camargo A.L., O'Donnell C.J. Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. Circulation 2007, 116:1128-1136.
31. Roy A.K., McCarthy C., Kiernan G., McGorrian C., Keenan E., Mahon N.G., Sweeney B. Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. Addiction 2012, 107:1132-1139.
32. Sanguinetti M.C., Mitcheson J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 2005, 26:119-124.
33. Tester D.J., Cronk L.B., Carr J.L., Schulz V., Salisbury B.A., Judson R.S., Ackerman M.J. Allelic dropout in long QT syndrome genetic testing: a possible mechanism underlying false-negative results. Heart Rhythm 2006, 3:815-821.
34. Wedam E.F., Bigelow G.E., Johnson R.E., Nuzzo P.A., Haigney M.C. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch. Intern. Med. 2007, 167:2469-2475.